ArticleNeurology2025
Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration in Black/African American Older Adults.Biomolecules · 2026Article
- Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans.The journal of prevention of Alzheimer's disease · 2026Observational
- The prognostic value of blood-based p-tau217 levels on progression to clinical impairment.medRxiv : the preprint server for health sciences · 2026Article
- Association of Fractional Anisotropy in White Matter Bundles with Plasma Biomarkers of Neurodegeneration and Glial Reactivity in Individuals with Cognitive Complaints without dementia.Research square · 2026Article
- Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms.NPJ dementia · 2026Article
- Combined use of plasma p-tau217, NfL, and GFAP predicts domain-specific cognitive decline in cognitively unimpaired and MCI individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesAlzheimer disease blood-based biomarkers are a cost-effective method for early detection. Few studies provide long-term follow-up of cognition in Black participants. We assessed biomarker association with cognitive decline and dementia risk in Black and White participants.
methodsPlasma biomarkers (neurofilament light chain, glial fibrillary acidic protein [GFAP], amyloid-β 42/40 ratio, phosphorylated tau at threonine 217 [pTau217]) were measured in participants from a community-based Chicago cohort without dementia at the time of blood draw. They were evaluated annually for up to 15 years for cognition and dementia. Data included medical history, blood tests (e.g., kidney function), Mini-Mental State Examination (MMSE) score, and APOEε4. Associations of biomarkers with comorbidities, cognitive decline, and risk of dementia were examined within racial groups. To examine racial differences, we repeated the analysis using a Mahalanobis-balanced 1:1 match on biological sex, age, education, Latino/non-Latino status, longitudinal data availability, and clinical status (hypertension, diabetes, glomerular filtration rate, body mass index [BMI], and heart disease).
resultsBiomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. Biomarker levels were similar across races. Within racial groups, the associations of biomarkers with multiple comorbidities (especially kidney dysfunction and BMI) remained after controlling for demographics, APOEε4 status, and dementia or death within 5 years. Men had lower GFAP than women (all DISCUSSION: pTau217 was highly associated with dementia risk and cognitive decline. The association of biomarkers with cognitive decline in Black and White participants was similar. Higher pTau217 was, however, associated with global and semantic memory decline in Black adults. Generalizability is a limitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.